National Health Act 1953 Amendment special arrangements under subsection 100(1) Chemotherapy Pharmaceuticals Access Program (No. PB 83 of 2009) (Cth)

COMMONWEALTH OF AUSTRALIA

Instrument number PB 83 of 2009

Amendment special arrangements under subsection 100(1) of the National Health Act 1953

I, DECLAN O’CONNOR-COX, Assistant Secretary, Access and Systems Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.

Dated 10 August 2009

DECLAN O’CONNOR-COX

Assistant Secretary

Access and Systems Branch

Department of Health and Ageing

Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access Program

1              Commencement

This instrument commences on 1 September 2009.

2              Amendment of PB 55 of 2009

Schedule 1 amends PB 55 of 2009.

Schedule 1        Amendments

[1]            After paragraph 14, insert the following paragraphs:

14A.    If a medical practitioner or an approved hospital authority on behalf of a medical practitioner, has written on a medication chart that has been prepared in accordance with paragraph 13, the four digit code mentioned in Schedule 1 or Schedule 3 for a chemotherapy pharmaceutical and circumstances:

(a) subparagraph 13(e) is taken to have been complied with; and

(b) the Medicare Australia CEO is taken to have authorised the medication chart.

14B.     Paragraph 14A applies to a medication chart only if there is a four digit code for the chemotherapy pharmaceutical and circumstances in Schedule 1 or Schedule 3 whichever applies.

1. Schedule 1, item dealing with Cladribine

omit all text and substitute in the columns in the order indicated:

Cladribine

In compliance with authority procedures set out in paragraph 14:

3180

Hairy cell leukaemia

1. Schedule 1, item dealing with Fotemustine

omit all text and substitute in the columns in the order indicated:

Fotemustine

In compliance with authority procedures set out in paragraph 14:

3181

Metastatic malignant melanoma

1. Schedule 1, item dealing with Irinotecan

omit all text and substitute in the columns in the order indicated:

Irinotecan

In compliance with authority procedures set out in paragraph 14:

3184

Metastatic colorectal cancer in patients with a World Health Organisation performance status of 2 or less

1. Schedule 1, item dealing with Raltitrexed

omit all text and substitute in the columns in the order indicated:

Raltitrexed

In compliance with authority procedures set out in paragraph 14:

3185

For use as a single agent in the treatment of advanced colorectal cancer

1. Schedule 1, item dealing with Topotecan

omit all text and substitute in the columns in the order indicated:

Topotecan

In compliance with authority procedures set out in paragraph 14:

3186

Advanced metastatic ovarian cancer after failure of prior therapy which includes a platinum compound

1. Schedule 2, item dealing with Carboplatin in the form Solution for
   I.V. injection 450 mg in 45 mL

omit from the column headed “Brand”:

Baxter Carboplatin

1. Schedule 2, item dealing with Cladribine in the form Injection 10 mg in 5 mL vial

omit from the column headed “Form”:

vial

1. Schedule 2, item dealing with Fludarabine in the form Powder for
   I.V. injection containing fludarabine phosphate 50 mg

in the column headed “Brand” insert in alphabetical order:

Fludarabine Actavis

1. Schedule 2, item dealing with Paclitaxel in the forms Solution concentrate for I.V. infusion 30 mg in 5 mL, Solution concentrate for I.V. infusion 100 mg in 16.7 mL and Solution concentrate for I.V. infusion 300 mg in 50 mL

omit from the column headed “Brand”:

Baxter Paclitaxel